Archives: Download File

Top Pharmaceutical Companies Trust PharmaLegacy For Their Bone Metastasis Studies

Creating novel bone and orthopedics models needs no justification in a world where new pathologies are constantly appearing and even evolving, especially when a large number of cancers metastasize to the bones. Be it melanomas, breast cancer, or colon cancer, once a tumor finds its way to a patient’s bones, survival rates drop dramatically. More than 100,000 cases of bone metastasis are diagnosed every year, which further calls for the hasty development of new treatment methods. Download the brochure to learn more about our Bone Metastasis Models.

Top Pharmaceutical Companies Trust PharmaLegacy For Their Preclinical Ophthalmology Studies

In the fourth century B.C, Plato wrote that light emanated from the eye, seizing objects in its ray, which allowed us to see them. Centuries later, our understanding of ocular anatomy and physiology has drastically improved. In addition, what was once perceived by humans of antiquity as a punishment from the gods is today perceived as what it truly is: pathological processes that stem at the molecular level, and manifest all the way up to the systemic level. Ophthalmic diseases have the potential to take away what many agree is the most important and valued of the five senses: our vision. at PharmaLegacy, we have a vision. A vision of a world where ophthalmic
diseases are history. Just like Plato’s extramission theory. Download the brochure to learn more.

Non-small cell lung cancer, colorectal cancer, and pancreatic cancer share many similarities: They cause innumerable deaths every year, have poor survival rates, and are a great burden on the entire healthcare system. However, they also happen to have one similarity that could potentially turn the tables: the KRAS gene. For decades, KRAS has been deemed as an un-targetable gene that plays a cardinal role in both the initiation and development of a plethora of cancers. This changed with recent breakthroughs targeting different KRAS inhibitors, spearheaded by some of our experts at PharmaLegacy. Download the brochure to learn more.

When developing a drug, and before releasing it into the market, there are certain milestones that cannot be bypassed when assessing a drug’s ADME properties and safety. This translates to a need for impeccable DMPK studies. For almost 15 years, PharmaLegacy’s experts have been honing their skills to provide your pipeline with the seamless DMPK studies they deserve.

Download the brochure for more information on our DMPK capabilities and to see sample data.

Rheumatoid Arthritis (RA) is an autoimmune disorder affecting up to 1% of the population, associated with significant morbidity and mortality if not treated aggressively. Justifiably, it has been a target of great interest to biotech and pharma companies because, although there are now many drugs available, no one single drug or class of drug is universally effective and all have toxicities that can limit their use.

Download our brochure to learn more about PharmaLegacy’s arthritis models and how NHPs can deliver more clinically relevant results.

Doing immuno-oncology drug discovery in a large pharmaceutical company means there is almost always a desire for more and different data to drive decision-making on potential new therapeutic compounds. That was exactly the situation a Senior Research Fellow at a Fortune 500 pharmaceutical company found himself in when he decided to work with PharmaLegacy to assess the activity of their novel compounds.

Download the case study and see what he had to say about his experiences working with PharmaLegacy as their immuno-oncology CRO.